219 related articles for article (PubMed ID: 22623731)
1. Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.
McCourt C; Maxwell P; Mazzucchelli R; Montironi R; Scarpelli M; Salto-Tellez M; O'Sullivan JM; Longley DB; Waugh DJ
Clin Cancer Res; 2012 Jul; 18(14):3822-33. PubMed ID: 22623731
[TBL] [Abstract][Full Text] [Related]
2. Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists.
McCann C; Crawford N; Majkut J; Holohan C; Armstrong CWD; Maxwell PJ; Ong CW; LaBonte MJ; McDade SS; Waugh DJ; Longley DB
Cell Death Dis; 2018 Oct; 9(11):1081. PubMed ID: 30349042
[TBL] [Abstract][Full Text] [Related]
3. Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells.
Logan IR; McClurg UL; Jones DL; O'Neill DJ; Shaheen FS; Lunec J; Gaughan L; Robson CN
Oncotarget; 2016 Nov; 7(46):74724-74733. PubMed ID: 27729622
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells.
Wilson C; Wilson T; Johnston PG; Longley DB; Waugh DJ
Mol Cancer Ther; 2008 Sep; 7(9):2649-61. PubMed ID: 18790747
[TBL] [Abstract][Full Text] [Related]
5. Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis.
Raclaw KA; Heemers HV; Kidd EM; Dehm SM; Tindall DJ
Prostate; 2008 Nov; 68(15):1696-706. PubMed ID: 18726983
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.
Ferrari AC; Alumkal JJ; Stein MN; Taplin ME; Babb J; Barnett ES; Gomez-Pinillos A; Liu X; Moore D; DiPaola R; Beer TM
Clin Cancer Res; 2019 Jan; 25(1):52-63. PubMed ID: 30224345
[TBL] [Abstract][Full Text] [Related]
7. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM
Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635
[TBL] [Abstract][Full Text] [Related]
8. FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells.
Cornforth AN; Davis JS; Khanifar E; Nastiuk KL; Krolewski JJ
Oncogene; 2008 Jul; 27(32):4422-33. PubMed ID: 18391984
[TBL] [Abstract][Full Text] [Related]
9. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
10. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
Gravina GL; Marampon F; Di Staso M; Bonfili P; Vitturini A; Jannini EA; Pestell RG; Tombolini V; Festuccia C
Prostate; 2010 Aug; 70(11):1166-78. PubMed ID: 20333699
[TBL] [Abstract][Full Text] [Related]
11. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
[TBL] [Abstract][Full Text] [Related]
12. Activation of AKR1C1/ERβ induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity.
Yun H; Xie J; Olumi AF; Ghosh R; Kumar AP
Oncotarget; 2015 May; 6(13):11600-13. PubMed ID: 25816367
[TBL] [Abstract][Full Text] [Related]
13. Stromal anti-apoptotic androgen receptor target gene c-FLIP in prostate cancer.
Ye H; Li Y; Melamed J; Pearce P; Wei J; Chiriboga L; Wang Z; Osman I; Lee P
J Urol; 2009 Feb; 181(2):872-7. PubMed ID: 19095249
[TBL] [Abstract][Full Text] [Related]
14. Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation.
Mawji IA; Simpson CD; Hurren R; Gronda M; Williams MA; Filmus J; Jonkman J; Da Costa RS; Wilson BC; Thomas MP; Reed JC; Glinsky GV; Schimmer AD
J Natl Cancer Inst; 2007 May; 99(10):811-22. PubMed ID: 17505076
[TBL] [Abstract][Full Text] [Related]
15. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis.
Hyer ML; Sudarshan S; Kim Y; Reed JC; Dong JY; Schwartz DA; Norris JS
Cancer Biol Ther; 2002; 1(4):401-6. PubMed ID: 12432255
[TBL] [Abstract][Full Text] [Related]
17. Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5α-dihydrotestosterone regulation.
Cardoso HJ; Figueira MI; Vaz CV; Carvalho TMA; Brás LA; Madureira PA; Oliveira PJ; Sardão VA; Socorro S
Cell Oncol (Dordr); 2021 Apr; 44(2):385-403. PubMed ID: 33464483
[TBL] [Abstract][Full Text] [Related]
18. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ
J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722
[TBL] [Abstract][Full Text] [Related]
19. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
Liu X; Gomez-Pinillos A; Liu X; Johnson EM; Ferrari AC
Prostate; 2010 Feb; 70(2):179-89. PubMed ID: 19790234
[TBL] [Abstract][Full Text] [Related]
20. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
